- Pharmalot had a post today, “Kennedy Circulates Biogenerics Bill,” regarding a new draft of a bill that would establish an abbreviated pathway for FDA approval of follow-on biologics.
- Rep. Jay Inslee (D-WA) and two co-sponsors introduced a new follow-on biologics bill in the House last week, H.R. 1956. See also Press Release; Bill Summary.
- In “Abbott Blinks, Big Pharma Cringes,” the Wall St. Journal Health Blog reported Monday about new developments in Abbott’s battle over patent rights with the Thai government.
- Recent comments by FTC and DOJ officials on reverse payment agreements were quoted by AP in “FTC Head Defiant Over Drug Co. Payments.”
- Last week, a new PhRMA-sponsored study concluded that authorized generics do not deter paragraph IV filings. These two blogs recently had excellent posts on the study: Antitrust Review and FDA Law Blog.
- A new paper on authorized generics, written by Tom Chen, appears in this month’s Virginia Law Review. The paper approaches the authorized generics issue from an antitrust law perspective.
Recent Posts
- Hikma v. Vanda: Oral Argument Recap
- Teva v. Lilly should not be read as creating a new 112 rule for method of use claims
- Should ANDA filers be using the PTAB to mount early challenges to OB patents?
- Switching to WordPress
- Judge Hughes concurrence highlights post grant review appeal standing issue for pharma cases
Orange Book Blog 
Leave a comment